Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal

Vincenza Granata 1, Damiano Caruso 2, Roberto Grassi 3,4, Salvatore Cappabianca 3, Alfonso Reginelli 3, Roberto Rizzati 5, Gabriele Masselli 6, Rita Golfierei 7,2, Marco Rengo 2, Daniele Regge 8,9, Giuseppe Lo Re 10, Silvia Pradella 11, Roberta Fusco 1, Lorenzo Faggioni 12, Andrea Laghi 2, Vittorio Miele 11, Emanuele Neri 4,12,* and Francesca Coppola 7

Article

Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal

Cancers 2021, 13, 2135. https://doi.org/10.3390/cancers13092135

Academic Editors: Alan Hutson and Song Liu

Received: 25 February 2021
Accepted: 26 April 2021
Published: 28 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Simple Summary: Structured reporting in oncologic imaging is becoming necessary and has recently been recognized by major scientific societies. Structured reports collect all Patient Clinical Data, Clinical Evaluations and relevant key findings of Rectal Cancer, both in staging and restaging, and can facilitate clinical decision-making.

Abstract: Background: Structured reporting (SR) in oncologic imaging is becoming necessary and has recently been recognized by major scientific societies. The aim of this study was to build MRI-based structured reports for rectal cancer (RC) staging and restaging in order to provide clinicians all critical tumor information. Materials and Methods: A panel of radiologist experts in abdominal imaging, called the members of the Italian Society of Medical and Interventional Radiology, was established. The modified Delphi process was used to build the SR and to assess the level of agreement in all sections. The Cronbach’s alpha (Cα) correlation coefficient was used to assess the internal consistency of each section and to measure the quality analysis according to the average inter-item correlation. The intraclass correlation coefficient (ICC) was also evaluated. Results: After the second Delphi round of the SR RC staging, the panelists’ single scores and sum of scores were 3.8 (range 2–4) and 169, and the SR RC restaging panelists’ single scores and sum of scores were 3.7 (range 2–4) and 148, respectively. The Cα correlation coefficient was 0.79 for SR staging and 0.81 for SR restaging. The ICCs for the SR RC staging and restaging were 0.78 (p < 0.01) and 0.82 (p < 0.01), respectively. The final SR version was built and included 53 items for RC staging and 50 items for RC restaging. Conclusions: The final version of the structured reports of MRI-based RC staging and restaging should be a helpful and promising tool for clinicians in managing cancer patients properly. Structured reports collect all...
Patient Clinical Data, Clinical Evaluations and relevant key findings of Rectal Cancer, both in staging and restaging, and can facilitate clinical decision-making.

**Keywords:** structured reporting; rectal cancer; magnetic resonance imaging; staging; re-staging

---

### 1. Introduction

The radiology report is an essential part of the imaging workflow, representing the main means of communication between radiologists, members of the multidisciplinary team and patients. Free text reporting (FTR) is still the most common format in clinical practice [1,2]. However, FTR may heterogeneously render core information; communication to referring physicians and the patient could be complicated and nonlinear [3,4]. Recently, the use of structured reporting (SR) has been recommended by several medical societies in order to standardize and improve the quality of the report content in comparison to FTR, thereby simplifying clinical decision-making [1–4]. Various studies, based on different medical imaging modalities, have shown that SR can reduce reporting times and facilitate clinical decision-making by improving the quality, accuracy and integrity of radiology reports. Therefore, both radiologists and referring physicians have favored SR over FTR [5,6]. When inexperienced residents use SR, it may lead to more thorough and comprehensive reports [6]. Furthermore, previous studies have indicated that SR may facilitate the use of artificial intelligence algorithms and might therefore be beneficial for scientific data analyses and the creation of homogeneous databases [7].

Magnetic resonance imaging (MRI) is the most accurate technique for rectal cancer (RC) pretreatment staging and restaging [6,8–10]. Tumor findings identified on baseline MRI (‘primary staging’) steer the subsequent clinical management, including whether neoadjuvant chemoradiotherapy (CRT) or short course radiotherapy prior to surgical resection is needed [11,12]. Post-treatment assessment MRI (‘restaging’) helps to determine the operating technique or alternative treatment, including the ‘watch and wait’ strategy [13,14].

The European Society of Gastrointestinal Abdominal Radiology (ESGAR) and the Society of Abdominal Radiology (SAR) consensus statements have recently recommended the use of “structured reporting” for rectal MRI and have provided rectal MRI report templates for the primary staging and restaging of rectal cancer [6,8,9]. Several proposals have been promoted by the major international societies of radiology to support the use of structured reporting, in 2018, the Italian Society of Medical and Interventional Radiology (SIRM) created an Italian warehouse of SR templates (mainly concerning oncologic imaging), which can be freely accessed by all SIRM members, with the purpose of being routinely used in a clinical setting.

The aim of the present study is to propose a structured reporting template for rectal cancer MRI in order to guide radiologists in the systematic reporting of neoplasm findings during the staging and re-staging phases to improve communication between radiologists and clinicians, particularly in non-referral centers.

### 2. Materials and Methods

#### 2.1. Panel Expert

As a result of a critical discussion between radiologist experts in abdominal imaging, a multi-round consensus-building Delphi exercise was carried out to develop a comprehensive focused structured reporting template for the MRIs of patients with RC.

A SIRM radiologist, with experience in informatics and abdominal imaging, created the first draft of the SR for MRI-based RC staging and restaging. A working team of nine experts from the Gastrointestinal Radiology and Imaging Informatics Chapters of SIRM was put together in order to iteratively revise the initial drafts, with the aim of reaching a final consensus on a staging report; eight experts from the Gastrointestinal Radiology...
and Imaging Informatics Chapters of the SIRM revised the initial drafts, with the aim of reaching a final consensus on the restaging report.

2.2. Selection of the Delphi Domains and Items

All the experts reviewed the literature data regarding the main scientific databases, including Pubmed, Scopus and Google Scholar, to assess papers on MRI findings of RC from December 2000 to December 2020. All members of the expert panel reviewed the full texts of the studies selected, and they each developed and shared the list of Delphi items via email and/or teleconference.

Both staging and restaging SR were divided into four sections: (a) Patient Clinical Data, (b) Clinical Evaluation, (c) Exam Technique and (d) Report. A dedicated section of significant images were added as part of the report.

The “Patient Clinical Data” section included patient clinical information, previous or family history of malignancies, risk factors and a genetic panel.

The “Clinical Evaluation” section collected previous examination results regarding computed tomography (CT), MRI, ultrasound (US), positron emission tomography (PET), rectal digital evaluation and histology.

The “Exam Technique” section included MRI acquisition parameters: specific MR scanner, sequences performed, contrast medium and eventual adverse reactions.

In the staging phase, the “Report” section included morphologic features, tumomr-node-metastasis (TNM) stage, according to Italian Association of Medical Oncology (AIOM) guidelines [15,16] and some pivotal prognostic factors, such as RC relationship with peritoneal reflection, colorectal metastases status, extra-mural venous invasion (EMVI) status, and tumor deposits. In the restaging phase, the “Report” section included data regarding post-treatment RC evaluation: presence/absence of a remaining tumor, presence/absence of fibrosis, presence/absence of mucinous degeneration, remaining tumor o’clock position, tumor length, distance from the anal verge and the anal rectal junction, yc-T stage, yc-T3 depth, presence/absence of remaining tumor deposits in the mesorectum, mesorectal node status, presence/absence of extra-mesorectal/lateral nodes, EMVI and colorectal metastases status.

Two Delphi rounds were carried out for each schematic report [17]. During the first round, each panelist independently contributed to refining the draft of each SR model by means of online meetings or email exchanges. The level of panelist agreement for each SR model was tested in the second Delphi, using a Google Form questionnaire shared by email. Each expert expressed individual comments for each specific part of the report (i.e., Patient Clinical Data, Clinical Evaluation, Exam Technique, Report, Findings and Conclusion) by using a four-point Likert scale (1 = strongly disagree, 2 = slightly disagree, 3 = slightly agree, and 4 = strongly agree) (Figure 1).

After the second Delphi round, the latest versions of the SR RC staging and restaging were generated on the dedicated Radiological Society of North America (RSNA) website (radreport.org) using a T-Rex template in Hypertext Markup Language (HTML) format in line with the IHE (Integrating Healthcare Enterprise) and the MRRT (management of radiology report templates) profile, accessible as open-source software, with the technical support of Exprivia. These determine both the format of the radiology report templates using both HTML5, and the transporting mechanism to request, get back and stock these schedules [18]. The radiology report was structured using a series of “codified queries” integrated into the T-Rex editor’s preselected sections [18].
2.3. Statistical Analysis

A modified Delphi process was used to express the agreement level for each section of the two SR models. All the ratings of the panelists for each section were analyzed using descriptive statistics (i.e., mean score, standard deviation and sum of scores). Mean scores of 3 and 4 were considered good and excellent, respectively.

To measure the internal consistency of the panelists’ ratings for each section of the SR, a quality analysis based on the average inter-item correlation was performed by means of using the Cronbach’s alpha (C$_\alpha$) correlation coefficient [19,20], which was determined after each Delphi round. The C$_\alpha$ test provides a measure of the internal consistency (related to the extent to which all items in a test measure the same concept) of a test or scale, and it is expressed as a number between 0 and 1. The closer the C$_\alpha$ coefficient is to 1.0, the greater the internal consistency of the items in the scale. An $\alpha$ coefficient $> 0.9$ was considered excellent, $\alpha > 0.8$ good, $\alpha > 0.7$ acceptable, $\alpha > 0.6$ questionable, $\alpha > 0.5$ poor and $\alpha < 0.5$ unacceptable. However, in the iterations, an $\alpha$ of 0.8 was considered to be a reasonable goal for internal reliability. The intraclass correlation coefficient (ICC) was also assessed.

Data analysis was carried out using the Matlab Statistic Toolbox (The MathWorks, Inc., Natick, MA, USA). A $p$-value $< 0.05$ was considered statistically significant.

3. Results

3.1. Structured Report RC Staging

The final SR version was built and included 15 items in the “Patient Clinical Data” section, eight items in the “Clinical Evaluation” section, eight items in the “Exam Technique” section, 20 items in the “Report” section, and two items in the “Conclusion” section. Overall, 53 items were included in the final version of the SR RC staging.

The results obtained during the first Delphi round are reported in Appendix A and those after the second Delphi round in Appendix C.
In the final version of the SR RC staging, the following parameters were included:

- In the “Exam technique” section: scanner field strength and renal function;
- In the “Report” section: primary tumor visible on imaging, location and positive lymph nodes with extracapsular extension.

### 3.2. Structured Report RC Restaging

The final SR version was built and included the same number of SR RC staging items for the “Patient Clinical Data” (15), “Clinical Evaluation” (8) and “Conclusions” (2) sections, while there were seven items in the “Exam Technique” section and 18 items in the “Report” section. In the final version of the SR RC restaging, a total of 50 items were included. All the results obtained after the first Delphi round are reported in Appendix B and the restaging SR obtained during the second Delphi round is reported in Appendix D.

The following parameters were included in the final version of the SR RC restaging:

- In the “Report” section: MRI Tumor Regression Grade (TRG) according to Dworak, Residual mass diffusion-weighted imaging (DWI) appearance, Mucin Response, and a healthy rectal wall appearance.

### 3.3. Consensus Agreement

After the second Delphi round of SR RC staging, the panelists’ single scores and sum of scores were calculated, and mean scores of 3.8 (range 2–4) and 169, respectively, were obtained (Table 1). All sections received a good rating, but the Patient Clinical Data” and “Clinical Evaluation” sections received lower mean scores (3.4 and 3.7, respectively) in comparison to the mean scores of the “Exam Technique”, “Report” and “Conclusion” (all 3.9) (Table 2).

| Panelist (P#)       | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | Sum of Scores |
|---------------------|----|----|----|----|----|----|----|----|----|----------------|
| Patient clinical data | 4  | 4  | 2  | 4  | 4  | 4  | 3  | 2  | 4  | 31              |
| Clinical evaluation  | 4  | 4  | 3  | 4  | 4  | 4  | 3  | 3  | 4  | 33              |
| Exam technique      | 4  | 4  | 4  | 4  | 4  | 4  | 3  | 4  | 4  | 35              |
| Report              | 4  | 4  | 3  | 4  | 4  | 4  | 4  | 4  | 4  | 35              |
| Conclusion          | 4  | 4  | 3  | 4  | 4  | 4  | 4  | 4  | 4  | 35              |

Table 1. Panelists’ single scores and sum of scores for RC staging reports (second round).

After the second Delphi round of SR RC restaging, the panelists’ single scores, mean scores and sum of scores were calculated and mean scores of 3.7 (range 2–4) and 148, respectively, were obtained (Table 3). In the SR RC restaging, all sections also obtained a good rating; the “Patient Clinical Data” and “Clinical Evaluation” sections received lower mean scores (3.4 and 3.5, respectively) in comparison to the mean scores of the “Exam Technique”, “Report”, and “Conclusion” (all 3.9) (Table 2).

| SR Section | Patient Clinical Data | Clinical Evaluation | Exam Technique | Report | Conclusion |
|------------|-----------------------|---------------------|----------------|--------|------------|
| Staging    | Mean value            | 3.4                 | 3.7            | 3.9    | 3.9        |
|            | Minimum value         | 2.0                 | 3.0            | 3.0    | 3.0        |
|            | Maximum value         | 4.0                 | 4.0            | 4.0    | 4.0        |
| Restaging  | Mean value            | 3.4                 | 3.5            | 3.9    | 3.9        |
|            | Minimum value         | 2.0                 | 2.0            | 3.0    | 3.0        |
|            | Maximum value         | 4.0                 | 4.0            | 4.0    | 4.0        |

Table 2. Mean and range values of scores for RC staging and restaging reports (second round).
Table 3. Panelists’ single scores and sum of scores for RC restaging reports (second round).

| Panelist (P#) | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | Sum of Scores |
|---------------|----|----|----|----|----|----|----|----|--------------|
| Patient clinical data | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 2 | 27 |
| Clinical evaluation | 4 | 4 | 3 | 4 | 4 | 4 | 3 | 3 | 28 |
| Exam technique | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 31 |
| Report | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 31 |
| Conclusion | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 31 |

After the second Delphi round, the Cα correlation coefficient reached 0.79 and 0.81 for RC staging and restaging reports, respectively. Furthermore, the ICC for the RC staging and restaging reports was 0.78 ($p < 0.01$) and 0.82 ($p < 0.01$), respectively.

4. Discussion

In the present study, the panel of experts demonstrated a high degree of agreement in defining the different points of the structured report. After the second Delphi round, the panelists’ mean scores and sum of scores related to SR models for the RC staging were 3.8 and 169, and for the restaging were 3.7 (range 2–4) and 148, respectively. All sections received more than a good rating in the second Delphi round. Moreover, the Cα correlation coefficient reached 0.79 and 0.81 for RC staging and restaging reports, respectively.

The strengths of SR have been extensively demonstrated by the major scientific societies, which have supported several initiatives, aimed at promoting the diffusion of SR, including the creation of RSNA standardized templates, the translation of RSNA templates into European languages, and the ESR papers published on SR [21,22]. In this study, the panel of radiologists expert in abdominal imaging demonstrated a high degree of agreement regarding the definition of various points of the staging and restaging structured report. All sections received a good rating; however, the weakest sections, for both staging and restaging, were “Patient Clinical Data” and “Clinical Evaluation”. The present report includes several sections: “Patient Clinical Data”, “Clinical Evaluation”, “Exam Technique” and “Report”. Some suggestions should be made for each of these sections.

The section “Patient Clinical Data” is designed to go beyond simple patient history collection, containing data regarding the family history of oncological pathologies and the exposure to different risk factors as well as data regarding any genetic mutations. These data could create the basis of a large database, allowing not only for the carrying out of epidemiological statistical analysis (i.e., family history and geographical distribution of cancer), but which could be used to build a Radiomics model by combining radiological features and clinical data [23]. In this context, the added value of genomic data could be used to develop a model of Radiogenomics, which was helpful regarding the highest level of personalized risk stratification and the advanced precision medicine process [24,25]. Radiogenomics could be a promising imaging biomarker that is useful for clinicians in early cancer diagnosis, prognosis prediction, cancer therapy selection, response to treatment and potential resistance to therapy evaluation [26,27].

Such a complex collection of patient clinical data has encountered some disagreement among experts who believe that users would consider the process to be too long and unsuitable for daily practice. Therefore, the presence of SR has been designed so that each section is independent from the other, allowing radiologists to fill out only the report section, although it is desirable that all the different sections be filled out. The present SR is also designed to be included in the picture archiving and communication system (PACS) in order to keep all patient data, so that some of the data only needs to be filled out once, at the first presentation.

Regarding the “Exam Technique” section, the authors believe that it is important to share data regarding the study acquisition protocols, by providing the indication to morphological sequences (i.e., T2w), eventual use of contrast medium, and the need for functional study sequences (i.e., DWI and/or Dynamic Contrast Enhancement [DCE]) [14,28–30]. The radiologist could obtain some textural analysis at a microscopic level using MRI.
morphological and functional sequences, even before these alterations become macroscopically appreciable [24]. This aspect has favored the adoption of different methods and sequences with which a patient can be evaluated. One of the main challenges of imaging is the lack of standardization; it is necessary to carry out similar protocols with a view to data reproducibility.

The “Report” section has a pivotal role; the advantages of SR over FTR include standardized terminology and structure, aspects required for adherence to diagnostic-therapeutic recommendations and for enrolment in clinical trials. Structured reporting reduces the ambiguity that may arise from non-conventional language, and enables better communication between radiologists and clinicians [31,32]. Moreover, lexicon standardization and data categorization could improve trainees’ learning [33], leading to more scientific research, guideline development and higher quality [34,35]. However, the adoption of SR could be hampered by resistance to change by some radiologists who look at SR as a too rigid text, limiting their expression, and leading to oversimplification. However, it should be highlighted that SR templates usually include a free text box to report any additional data that cannot be embedded in default template fields. Furthermore, some radiologists have stated that SR could diminish the professional standing of a radiologist, comparing SR to a laboratory report [36]. An additional limitation could be represented by reduced radiologist concentration on examinations due to keeping their attention focused on the SR template. This is supported by psycho-perceptive considerations, as by distracting the radiologists from images, SR could compromise the mental process leading from image observation to diagnosis, causing errors, longer reporting times and reduced productivity [36]. The main limitations of SR, which hinder its diffusion, were shown in the survey launched by the Imaging Informatics Chapter of the SIRM. In particular, it has emerged that the majority of SIRM radiologist members were open to the possibility of using SR; however, they were also concerned that its adoption in their real working life could lead to semantic, technical and professional issues [37].

The present SR is based on a multi-round consensus-building Delphi exercise to develop a comprehensive focus on the structured reporting template for MRI of patients with rectal cancer as a result of a critical discussion between radiologist experts in abdominal Imaging. Unlike the SR in this study, the SR adopted by the ESGAR is based on a consensus method that was an adaptation of the RAND-UCLA Appropriateness Method (RAM), which combines postal and face-to-face rounds. Regarding the “Report” section, the staging and re-staging templates are similar; however, in the present re-staging template, MRI Tumor Regression Grade (TRG) according to Dworak, Mucin Response and a healthy rectal wall appearance, items not assessed by ESGAR, were introduced.

In the present SR, the possibility of combining radiological and clinical patient data also opens the way to create a large database, allowing not only for performing epidemiological statistical analysis, but also building a Radiomics model.

Despite the promising results obtained, the present study has some limitations. First, the expert panel was made up of only radiologists; therefore, a multidisciplinary approach, which is the basis of patient management today, is lacking. A multidisciplinary validation of SR would be appropriate, taking into account the needs of oncologists and surgeons. Second, the expert panelists were of the same nationality; for this reason, there was a relatively small number of expert panelists selected. The participation of opinion leaders from multiple countries would allow for broader sharing and would increase the consistency of the structured report. Finally, this study was not aimed at assessing the impact of the structured report on the diagnosis and management of rectal cancer patients. This issue will be discussed in the forthcoming studies.

5. Conclusions

In conclusion, MRI-based structured reporting for rectal cancer should be used to standardize and structure staging and restaging phases, by providing oncologists and surgeons with all the necessary key findings in order to manage these patients. The use of
SR could also be helpful in enrolling patients in clinical trials and in building a complete data warehouse that is useful for future scientific investigations.

**Author Contributions:** Each author has participated sufficiently to take public responsibility for the manuscript content. Data curation, F.C.; Formal analysis, V.G. and F.C.; Methodology, V.G., D.C., R.G. (Roberto Grassi), S.C., A.R., R.R., G.M., R.G. (Rita Golfieri), M.R., D.R., G.L.R., S.P., R.F., L.F., A.L., V.M., E.N. and F.C.; Supervision, R.G.; Writing—original draft, V.G. and E.N.; Writing—review & editing, V.G. and E.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** This study was performed according to regulations issued by the local Institutional Review Board.

**Informed Consent Statement:** All patient gave their written informed consent for research purposes.

**Data Availability Statement:** All data are presented in the manuscript.

**Conflicts of Interest:** The authors have no conflict of interest to be disclosed.

### Appendix A

#### Appendix A.1. Patient Clinical Data

| FIELD                                      | DETAIL                  | NOTES/APPROVED VALUES |
|--------------------------------------------|-------------------------|-----------------------|
| **ANTHRROPOMETRIC DATA**                   |                         |                       |
| Weight                                     | Numeric [Kg]            |                       |
| Height                                     | Numeric [cm]            |                       |
| BMI                                        | Numeric [calculated automatically] |                   |
| BSA                                        | Numeric [calculated automatically] |                   |
| Age                                        | Numeric                 |                       |
| Age class                                  | <50                     |                       |
|                                             | >50                     |                       |
| **PERSONAL RATINGS**                       |                         |                       |
| Family History for colorectal cancer       | Kind of relationship    |                       |
|                                             | Mother                  |                       |
|                                             | Father                  |                       |
|                                             | Brothers Sisters        |                       |
|                                             | Maternal grandparents   |                       |
|                                             | Paternal grandparents   |                       |
|                                             | Uncles/aunts            |                       |
|                                             | Other                   |                       |
| Notes                                      |                         |                       |
| Family History for cancer                  | Kind of relationship    |                       |
| (detail visible only if “Yes” and repeatable) |                         |                       |
|                                             | Mother                  |                       |
|                                             | Father                  |                       |
|                                             | Brothers Sisters        |                       |
|                                             | Maternal grandparents   |                       |
|                                             | Paternal grandparents   |                       |
|                                             | Uncles/aunts            |                       |
|                                             | Other                   |                       |
| Notes                                      |                         |                       |
| Personal background for other malignancies | Yes/No                  |                       |
|                                             | Notes                   |                       |
| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| **Hereditary genetic alterations**<br>(detail visible only if “Yes” and repeatable) | | |
| Yes/No | | |
| Type | • Polyposis associated with MutYH or MAP mutation<br>• Colon attenuated polyposis (AFAP)<br>• Classic colon polyposis (FAP)<br>• Lynch syndrome | |
| Notes | | |
| **Predisposing pathologies**<br>(detail visible only if “Yes” and repeatable) | | |
| Yes/No | | |
| Type | • Diabetes<br>• hyper cholesterolemia<br>• Hypertension<br>• Hypertriglyceridermia<br>• Crohn’s disease<br>• rectal ulcerative colitis<br>• Metabolic syndrome | |
| Notes | | |
| **Risk factors**<br>(detail visible only if “Yes” and repeatable) | | |
| | | |
| Smoker | | |
| Yes/No | | |
| **SMOKING DETAILS**<br>(visible only if indicated Smoker = yes) | | |
| | | |
| Smoker | • Smoker<br>• Current<br>• Former smoker | |
| Cigarette smoking | Yes/No | |
| Number of cigarettes per day [if current smoker] | • weak (<15)<br>• strong (≥15) | |
| Years of smoking | Numeric | |
| Number of years of cessation [if ex-smoker] | • <15<br>• ≥15 | |
| Packs/year [if ex-smoker or current smoker] | Numeric<br>[calculated automatically]<br>(No. of cigarettes per day × smoke years/20) | |
| Electronic cigarette | Yes/No | |
| Number of refills per day [if electronic cigarette = yes] | Numeric | |
| Number of years [if electronic cigarette = yes] | Numeric | |
| Notes | | |
| **High alcohol intake**<br>(more than 1 glass per day, if female more than a 2 glasses per day, if male) | Yes/No | |
| | Yes<br>• No | |
| **High meat intake**<br>(eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola]) | Yes/No | |
| | Yes<br>• No | |
| **High intake of salami**<br>(eats cured meats more than once a week [salami, mortadella, sausage, frankfurters ...]) | Yes/No | |
| | Yes<br>• No | |
| **Poor vegetable intake**<br>(1 serving is considered as a salad plate [at least 50 g] or half a plate of cooked/ raw vegetables or a glass of juice/centrifuge) | Yes/No | |
| | Yes<br>• No | |
| **Poor fruit intake**<br>(1 whole fruit, such as apple, pear or orange, or 2/3 small fruits, such as apricots plums or fruit salad bowl) | Yes/No | |
| | Yes<br>• No | |
| Notes | | |
| **Microsatellite instability** | Yes/No | |
| Notes | | |
### ALLERGIES AND ADVERSE REACTIONS

| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| Allergies (detail visible only if “Yes” and repeatable) | Yes/No | |
| Type | Drug | MDC | Not a Drug |
| Active substance/molecule | [if drug or MDC allergy] | |
| Commercial name | [if drug or MDC allergy] | |
| Notes | | |
| PREVIOUS adverse reactions (detail visible only if “Yes” and repeatable) | Yes/No | |
| Date | Month/year [mm/yyyy] | |
| Description | | |
| Grade | Mild | Moderate | Severe |
| Timing | Early | Late |
| Notes | | |

### Appendix A.2. Clinical Evaluation

| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| Clinical Data | Yes/No | |
| Previous examination (detail visible only if “Yes” and repeatable) | Type | CT | MRI | US | PET | Others |
| Date | | |
| Notes | | |
| Rectal exploration performed (detail visible only if “Yes”) | Yes/No | |
| Affected side | Front | Right | Left | Rear |
| Distance to anal verge | Numeric [cm] |
| Distance to anorectal junction | Numeric [cm] |
| Sphincter involvement | Yes/No |
| Notes | | |
| Trans-rectal ultrasound performed (detail visible only if “Yes”) | Yes/No | |
| Affected side | Front | Right | Left | Rear |
| Distance to anal verge | Numeric [cm] |
| Distance to anorectal junction | Numeric [cm] |
| Sphincter involvement | Yes/No |
| Notes | | |
| Histological examination of biopsy | Yes/No | |
| Notes | | |

| Field | Notes/Allowed Values |
|-------|----------------------|
| CEA dosage | Numeric |
| Blood exam completed | Numeric |
| Creatinine | Numeric |
| Liver function | Normal | Compromised |
### Appendix A.3. Exam Technique

| FIELD                  | DETAIL                                      | NOTES/ALLOWED VALUES                        |
|------------------------|---------------------------------------------|---------------------------------------------|
| Examination Data       |                                             |                                             |
| Examination date       |                                             | Post neoadjuvant treatment                  |
| Clinical indication    |                                             | • FSE T2 weighted in axial plane            |
|                        |                                             | • FSE T2 weighted in sagittal plane         |
|                        |                                             | • FSE T2 weighted in coronal plane          |
|                        |                                             | • FSE T1 weighted in axial plane            |
|                        |                                             | • DWI                                        |
|                        |                                             | • ADC                                        |
| Sequences              |                                             |                                             |
| MDC                    |                                             | Yes/No                                       |
| (detail visible only if “Yes”) |                                         |                                             |
| Active principle       |                                             |                                             |
| Commercial name        |                                             |                                             |
| Dosage                 | Numeric [mL]                                |                                             |
| Flow rate              | Numeric [mL/s]                              |                                             |
| Concentration          | Numeric [mg I/mL]                           |                                             |
| Notes                  |                                             |                                             |
| Premedication for allergy |                                         | Yes/No                                       |
|                        |                                             | Notes                                        |
| Preventive hydration for kidney failure | GFR (Glomerular Filtration Rate) | Numeric [mL/min]                             |
|                        |                                             | GFR = 141 × min (serum creatinine/kappa, 1) |
|                        |                                             | alpha × max (serum creatinine/kappa, 1) −   |
|                        |                                             | 1.209 × 0.993Age × Gender × Race            |
|                        |                                             | https://www.merckmanuals.com/medical-      |
|                        |                                             | calculators/GFR_CKD_EPI-it.htm,            |
|                        |                                             | accessed on 21 January 2021                 |
| ADVERSE EVENTS         |                                             |                                             |
| Ongoing adverse events | (detail visible only if “Yes”)               | Yes/No                                       |
|                        | Grade                                       | Mild (Symptoms are generally self-limiting   |
|                        |                                             | without evidence of progression and should   |
|                        |                                             | be monitored)                                |
|                        |                                             | Moderate (Symptoms are more pronounced and   |
|                        |                                             | some can become severe if left untreated)   |
|                        |                                             | Severe (Symptoms are often life-threatening) |
|                        | Timing                                      | Early                                        |
|                        |                                             | Late                                         |
|                        |                                             | Numeric [min] (optional)                     |
| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| ALLERGIC/ALLERGIC-LIKE | mild | • Ponfi sparse/itchy  
• Skin edema  
• Mild itching/velvety in the throat  
• Nasal congestion  
• Sneezing  
• Conjunctivitis  
• Runny nose  
| Moderate | • Widespread wheals/intense itching  
• Diffuse skin erythema  
• Facial edema without dyspnea  
• Feeling of suffocation or hoarseness  
• Shortness of breath/mild bronchospasm  
• Shortness of breath/mild bronchospasm without hypoxia  
| Severe | • Dyspnea  
• Erythema—diffuse mucosal-cutaneous manifestations  
• Laryngeal edema with stridor and/or hypoxia  
• Shortness of breath/bronchospasm  
• Significant hypoxia  
• Anaphylactic shock (severe hypotension and bradi-tachi-arrhythmia)  
| NOT ALLERGIC | Mild | • Slight limited nausea/vomiting  
• Chills/heat/transient redness  
• Headache/dizziness/anxiety/impaired taste  
• Mild increase in blood pressure  
• Self-resolving vaso-vagal reaction  
| Moderate | • Prolonged nausea/vomiting  
• High blood pressure  
• Isolated chest pain  
• Vaso-vagal reaction  
| Severe | • Vaso-vagal reaction resistant to treatment  
• Arrhythmia  
• Seizures  
• Marked arterial hypertension  
| Treatment Type | • Observation  
• Drug administration + field notes for detail  
• Called resuscitator  
| Event resolution | • Spontaneously  
• After therapy  
• After hospitalization  
• Other  
| Notes | | |

**Appendix A.4. Report**

| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| Tumor Staging | | |
| Position | Type | Low  
Medium  
High  
| Notes | | |
| Distance from the inferior border of the tumor to the anal verge | Numeric [cm] | |
| FIELD                                      | DETAIL                          | NOTES/ALLOWED VALUES                  |
|-------------------------------------------|---------------------------------|---------------------------------------|
| Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm]                  |                                       |
| Craniocaudal tumor length                 | Yes/No                          | Numeric [cm]                          |
| Morphology                                | Type                            | Solid polypoid                        |
|                                           |                                 | Vegetative                           |
|                                           |                                 | Ulcerated                            |
|                                           |                                 | Ring finger                          |
|                                           |                                 | Semianular                           |
|                                           |                                 | Flat                                 |
|                                           |                                 | Mucinoso                              |
| Notes                                     |                                 |                                       |
| Localization                              | Type                            | Front                                 |
|                                           |                                 | Back                                  |
|                                           |                                 | Lateral                               |
|                                           |                                 | Right                                 |
|                                           |                                 | Left                                  |
| Local invasion                            | Type                            | Submucosa infiltration (T1)           |
|                                           |                                 | Muscularis infiltration (T2)          |
|                                           |                                 | Distance between the outermost edge of the muscularis propria and the maximum extramural spread of the tumor <1.00 mm (T3a) |
|                                           |                                 | Distance between the outermost edge of the muscularis propria and the maximum extramural spread of the tumor 1.01–5.00 mm (T3b) |
|                                           |                                 | Distance between the outermost edge of the muscularis propria and the maximum extramural spread of the tumor 5.01–15.00 mm (T3c) |
|                                           |                                 | Distance between the outermost edge of the muscularis propria and the maximum extramural spread of the tumor >15.01 mm (T3d) |
|                                           |                                 | Infiltration of the adjacent organs (T4a) |
|                                           |                                 | Visceral peritoneum drilling (T4b)    |
| Notes                                     |                                 |                                       |
| Anal sphincter complex involvement (detail visible only if “Yes”) | Sphincter invasion thickness     | Internal sphincter                   |
|                                           |                                 | Intersphincteric plane                |
|                                           |                                 | External sphincter                   |
|                                           | Height sphincter invasion       | High                                  |
|                                           |                                 | Medium                                |
|                                           |                                 | Distal                                |
| Notes                                     |                                 |                                       |
| CRM Involvement                           | The shortest distance between the outermost part of the rectal tumor and the MRF | Numeric [mm]                          |
| Margins                                   | Type                            | Involvement                           |
|                                           | (multiple choice)               | Not Involvement                       |
|                                           |                                 | Front                                 |
|                                           |                                 | Back                                  |
|                                           |                                 | Lateral                               |
|                                           |                                 | Right                                 |
|                                           |                                 | Left                                  |
| Minimum distance localization              | Type                            | Above                                 |
|                                           |                                 | Below (reversal of the MCR)          |
| Relationship with anterior peritoneal reflection | Type                     | Above                                 |
|                                           |                                 | Below (reversal of the MCR)          |
**FIELD** | **DETAIL** | **NOTES(ALLOWED VALUES)**  
--- | --- | ---  
**LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESOCT ADIPOSE TISSUE** |  
Yes/No  
**Lymph node metastases (detail visible only if “Yes”)** |  
Type |  
- Certain  
- Suspicious, >9 mm in size  
- Suspicious, at least 2, 5–8 mm in size  
- Suspicious, at least 3, <5 mm in size  
**Morphology** |  
- Regular morphology  
- Irregular morphology  
- Heterogeneous signal  
Notes  
**Tumor deposits into mesorectal space (detail visible only if “Yes”)** | Notes  
**Extramural vascular invasion** | Yes/No  
**CONCLUSION**  
**Diagnosis** |  
(TNM classification, AJCC-UICC 2017)  
$cT, N, M, Stage$ |  
$T0$ |  
$T1$ |  
$T2$ |  
$T3$ |  
$T4$  
$Tis$ |  
$Diagnosis$ |  
(classification, $cT, N, M, Stage$, 8th Edition) |  
$T0$ |  
$T1$ |  
$T2$ |  
$T3$ |  
$T4$  
Notes  
**Annotations and comments**  
**Appendix A.5. Images**  
**FIELD** | **DETAIL** | **NOTES(ALLOWED VALUES)**  
--- | --- | ---  
**ANTHROPOMETRIC DATA** |  
Weight | Numeric [Kg]  
Height | Numeric [cm]  
BMI | Numeric [calculated automatically]  
BSA | Numeric [calculated automatically]  
Age | Numeric  
age class |  
- <50  
- >50  
**PERSONAL RATINGS** |  
Yes/No  
**Family History for colorectal cancer (detail visible only if “Yes” and repeatable)** | Kind of relationship |  
- Mother  
- Father  
- Brothers Sisters  
- Maternal grandparents  
- Paternal grandparents  
- Uncles/aunts  
- Other  
Notes
| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| Family History for cancer (detail visible only if “Yes” and repeatable) | Kind of relationship | - Mother  
- Father  
- Brothers/Sisters  
- Maternal grandparents  
- Paternal grandparents  
- Uncles/aunts  
- Other |
| Personal background for other malignancies | Yes/No | Notes |
| Hereditary genetic alterations (detail visible only if “Yes” and repeatable) | Type | - Polyposis associated with MutYH or MAP mutation  
- Colon attenuated polyposis (AFAP)  
- Classic colon polyposis (FAP)  
- Lynch syndrome |
| Predisposing pathologies (detail visible only if “Yes” and repeatable) | Type | - Diabetes  
- Hypercholesterolemia  
- Hypertension  
- Hypertriglyceridemia  
- Crohn’s disease  
- Rectal ulcerative colitis  
- Metabolic syndrome |
| Risk factors (detail visible only if “Yes” and repeatable) | Smoker | Yes/No |
| | Cigarette smoking | Yes/No |
| | Number of cigarettes per day [if current smoker] | weak (<15)  
strong (≥15) |
| | Years of smoke | Numeric |
| | Number of years of cessation [if ex-smoker] | ≤15  
>15 |
| | Packs/year [if ex-smoker or current smoker] | calculated automatically | (No. of cigarettes per day × smoke years/20) |
| | Electronic cigarette | Yes/No |
| | Number of refills per day [if electronic cigarette = yes] | Numeric |
| | Number of years [if electronic cigarette = yes] | Numeric |
| | High alcohol intake | Yes (more than 1 glass per day, if female, more than 2 glasses per day, if male)  
No |
| | High meat intake | Yes (eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola])  
No |
### Risk factors

**High intake of salami**
- **Yes** (eats cured meats more than once a week [salami, mortadella, sausage, frankfurters . . . ])
- **No**

**Poor vegetable intake**
- **Yes** (less than 2 times per day)
- **No** (1 serving is considered as a salad plate [at least 50 g] or half a plate of cooked/raw vegetables or a glass of juice/centrifuge)

**Poor fruit intake**
- **Yes** (less than 3 whole fruits per day)
- **No** (1 whole fruit, such as apple, pear or orange, or 2/3 small fruits, such as apricots plums or fruit salad bowl)

### Microsatellite instability

- **Yes/No**

### Allergies and Adverse Reactions

**Allergies**
- **Yes/No**

**Type**
- **Drug**
- **MDC**
- **Not a Drug**

**Active substance/molecule [if drug or MDC allergy]**

**Commercial name [if drug or MDC allergy]**

- **Notes**

### Previous adverse reactions

**Yes/No**

**Date**

**Month/year [mm/yyyy]**

**Description**

**Grade**
- **Mild**
- **Moderate**
- **Severe**

**Timing**
- **Early**
- **Late**

- **Notes**

### Clinical Evaluation

**Clinical Data**

- **Yes/No**

**Previous examination**

- **Type**
  - **CT**
  - **MRI**
  - **US**
  - **PET**
  - **Others**

- **Date**
- **Notes**

**Rectal exploration performed**

- **Affected side**
  - **Front**
  - **Right**
  - **Left**
  - **Rear**

- **Distance to anal verge**
  - **Numeric [cm]**

- **Distance to anorectal junction**
  - **Numeric [cm]**

- **Sphincter involvement**
  - **Yes/No**

- **Notes**
### FIELD DETAIL NOTES/ALLOWED VALUES

| FIELD                                                                 | DETAIL                                      | NOTES/ALLOWED VALUES                  |
|-----------------------------------------------------------------------|---------------------------------------------|----------------------------------------|
| Trans-rectal ultrasound performed (detail visible only if “Yes”)      | Yes/No                                      | Front, Right, Left, Rear               |
| Affected side                                                         |                                             |                                        |
| Distance to anal verge                                               | Numeric [cm]                                 |
| Distance to anorectal junction                                       | Numeric [cm]                                 |
| Sphincter involvement                                                | Yes/No                                      |                                        |
| Notes                                                                |                                             |                                        |
| Histological examination of biopsy                                   | Yes/No                                      |                                        |
| Notes                                                                |                                             |                                        |
| CEA dosage                                                           | Numeric                                     |                                        |
| Blood exam completed                                                 | Numeric                                     |                                        |
| Creatinine                                                           | Numeric                                     |                                        |
| Liver function                                                       | Normal, Compromised                         |                                        |

### Appendix B.3. Exam Technique

| FIELD                | DETAIL                                      | NOTES/ALLOWED VALUES                  |
|----------------------|---------------------------------------------|----------------------------------------|
| Examination Data     |                                             |                                        |
| Examination date     |                                             |                                        |
| Clinical indication  | Post neoadjuvant treatment                  |                                        |
| Sequences            |                                             | FSE T2 weighted in axial plane         |
|                      |                                             | FSE T2 weighted in sagittal plane       |
|                      |                                             | FSE T2 weighted in coronal plane        |
|                      |                                             | FSE T1 weighted in axial plane          |
|                      |                                             | DWI, ADC                                |
| MDC                  |                                             |                                        |
| MDC (detail visible only if “Yes”)                                   | Yes/No                                      |                                        |
| Active principle      |                                             |                                        |
| Commercial name       |                                             |                                        |
| Dosage                | Numeric [mL]                                 |                                        |
| Flow rate             | Numeric [mL/s]                               |                                        |
| Concentration         | Numeric [mg I/mL]                            |                                        |
| Notes                 |                                             |                                        |
| Premedication for allergy                                        | Yes/No                                      |                                        |
| Notes                 |                                             |                                        |
| Preventive hydration for kidney failure                             |                                             |                                        |
| GFR (Glomerular Filtration Rate)                                    |                                             |                                        |
| GFR = 141 × min (serum creatinine/kappa, 1) alpha × max (serum creatinine/kappa, 1) – 1.209 × 0.993Age × Gender × Race https://www.merckmanuals.com/medical-calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021 |                                        |

### ADVERSE EVENTS
| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| Yes/No | Date and event time | Ongoing adverse events (detail visible only if “Yes”) |
| Grade | | Mild (Symptoms are generally self-limiting without evidence of progression and should be monitored) |
| Timing | | Moderate (Symptoms are more pronounced and some can become severe if left untreated) |
| | | Severe (Symptoms are often life-threatening) |
| Numeric [min] (optional) | | ALLERGIC/ALLERGIC-LIKE |
| | Mild | Ponfi sparse/itchy |
| | | Skin edema |
| | | Mild itching/velvety in the throat |
| | | Nasal congestion |
| | | Sneezing |
| | | Conjunctivitis |
| | | Runny nose |
| | Moderate | Widespread wheals/intense itching |
| | | Diffuse skin erythema |
| | | Facial edema without dyspnea |
| | | Feeling of suffocation or hoarseness |
| | | Shortness of breath/mild bronchospasm without hypoxia |
| | Severe | Dyspnea |
| | | Erythema—diffuse mucosal-cutaneous manifestations |
| | | Laryngeal edema with stridor and/or hypoxia |
| | | Shortness of breath/bronchospasm |
| | | Significant hypoxia |
| | | Anaphylactic shock (severe hypotension and bradi-tachi-arrhythmia) |
| Type | | NOT ALLERGIC |
| | Mild | Slight limited nausea/vomiting |
| | | Chills/heat/transient redness |
| | | Headache/dizziness/anxiety/impaired taste |
| | | Mild increase in blood pressure |
| | | Self-resolving vaso-vagal reaction |
| | Moderate | Prolonged nausea/vomiting |
| | | High blood pressure |
| | | Isolated chest pain |
| | | Vaso-vagal reaction |
| Event resolution | Severe | Vaso-vagal reaction resistant to treatment |
| | | Arrhythmia |
| | | Seizures |
| | | Marked arterial hypertension |
| Notes | Treatment Type | Observation |
| | | Drug administration + field notes for detail |
| | | Called resuscitator |
| | | Spontaneously |
| | | After therapy |
| | | After hospitalization |
| | | Other |
### Appendix B.4. Report

| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|-----------------------|
| Tumor Staging | Remaining tumor | ● No, fully normalized rectal wall (complete response)  
● No, fibrotic thickening of the wall without a residual mass (complete or near full response)  
● Yes, residual mass (and/or high signal on DWI) |
| | Notes | ● yT1–2  
● yT3—yT3a o yT3b (extramural extension ≤ 5 mm)  
● yT3—yT3c o yT3d (extramural extension > 5 mm)  
● yT4, extension to adjacent organs |
| | yT-stage | ● Internal sphincter  
● Intersphincteric plane  
● External sphincter |
| | Notes | ● High  
● Medium  
● 1/3 away from the channel |
| | Distance from the inferior border of the tumor to the anal verge | Numeric [cm] |
| | Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm] |
| | Craniocaudal tumor length | Numeric [cm] |
| | Anal sphincter complex involvement | Yes/No |
| | (detail visible only if “Yes”) | Type (multiple choice) |
| | | ● Internal sphincter  
● Intersphincteric plane  
● External sphincter |
| | Localization | ● High  
● Medium  
● 1/3 away from the channel |
| CRM Involvement | The shortest distance between the outermost part of the rectal tumor and the MRF | Numeric [mm] |
| | Margins | ● Involvement  
● Not Involvement |
| | Localization | Type (multiple choice) |
| | | ● Front  
● Back  
● Lateral  
● Right  
● Left |
| Relationship with anterior peritoneal reflection | O-clock position | ● Above  
● Below (reversal of the MCR) |
| LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESORECTAL ADIPOSE TISSUE | Lymph node metastases | Yes/No |
| | (detail visible only if “Yes”) | Type |
| | | ● yN0 (no node remaining or only nodes < 5 mm)  
● yN + (presence of nodes with short axis diameter ≥ 5 mm) |
| | Number of suspected residual mesorectal lymph nodes (≥5 mm) | Numeric |
| | Number of suspected extra mesorectal lymph nodes (≥5 mm) | Numeric |
| Tumor deposits into mesorectal space | Notes | Yes/No |
| (detail visible only if “Yes”) | Numeric |
| Extramural vascular invasion | Notes | Yes/No |
## Diagnosis

| Field | Detail | Notes/Allowed Values |
|-------|--------|----------------------|
| cT, N, M, Stage | (TNM classification, 8th Edition, AJCC-UICC 2017) | TX, T0, T1, T2, T3, T4, Nx, N0, N1a, N1b, N1c, Mx, M0, M1, Stage 0, Stage I, Stage IIa, Stage IIb, Stage IIIa, Stage IIIb, Stage IIIc, Stage IV |

### Annotations and comments

**Appendix B.5. Images**

| Field | Detail | Notes/Allowed Values |
|-------|--------|----------------------|
| Significant key images | Images | |

## Appendix C

### Appendix C.1. Patient Clinical Data

| Field | Detail | Notes/Allowed Values |
|-------|--------|----------------------|
| **ANTHROPOMETRIC DATA** | | |
| Weight | Numeric [Kg] | |
| Height | Numeric [cm] | |
| BMI | Numeric [calculated automatically] | |
| BSA | Numeric [calculated automatically] | |
| Age | Numeric | |
| age class | | <50, >50 |

### PERSONAL RATINGS

| Field | Detail | Notes/Allowed Values |
|-------|--------|----------------------|
| Family History for colorectal cancer (detail visible only if “Yes” and repeatable) | Kind of relationship | Mother, Father, Brothers/Sisters, Maternal grandparents, Paternal grandparents, Uncles/aunts, Other |
| Notes | | |
| Family History for cancer (detail visible only if “Yes” and repeatable) | Kind of relationship | Mother, Father, Brothers/Sisters, Maternal grandparents, Paternal grandparents, Uncles/aunts, Other |
| Notes | | |
| Personal background for other malignancies | Yes/No | |
| Notes | | |
| Hereditary genetic alterations (detail visible only if “Yes” and repeatable) | Type | Polyposis associated with MutYH or MAP mutation, Colon attenuated polyposis (AFAP), Classic colon polyposis (FAP), Lynch syndrome |
| Notes | | |
| FIELD                          | DETAIL                                                                 | NOTES/ALLOWED VALUES |
|-------------------------------|------------------------------------------------------------------------|---------------------|
| **Predisposing pathologies**  | **Type**                                                               |                     |
|                               | Yes/No                                                                 |                     |
|                               | • Diabetes                                                             |                     |
|                               | • Hypercholesterolemia                                                |                     |
|                               | • Hypertension                                                        |                     |
|                               | • Hypertriglyceridemia                                                |                     |
|                               | • Crohn’s disease                                                     |                     |
|                               | • Rectal ulcerative colitis                                           |                     |
|                               | • Metabolic syndrome                                                  |                     |
| **Notes**                     |                                                                        |                     |
| **Risk factors**              | **Smoker**                                                            | Yes/No              |
|                               | Yes/No                                                                 |                     |
|                               | **SMOKER DETAILS** (visible only if indicated Smoker = yes)            |                     |
|                               | Smoker                                                                 |                     |
|                               | (visible only if indicated Smoker)                                    |                     |
|                               | Cigarette smoking                                                     | Yes/No              |
|                               | • weak (<15)                                                          |                     |
|                               | • strong (≥15)                                                        |                     |
|                               | Years of smoke                                                       | Numeric             |
|                               | • ≤15                                                                 |                     |
|                               | • >15                                                                 |                     |
|                               | Packs/year                                                            | Numeric             |
|                               | (if ex-smoker or current smoker)                                      |                     |
|                               | Electronic cigarette                                                 | Yes/No              |
|                               | Number of refills per day                                             | Numeric             |
|                               | (if electronic cigarette = yes)                                       |                     |
|                               | Number of years                                                       | Numeric             |
|                               | (if electronic cigarette = yes)                                       |                     |
|                               | High alcohol intake                                                  | Yes/No              |
|                               | (more than 1 glass per day, if female, more than a 2 glasses per day, if male) |                     |
|                               | High meat intake                                                      | Yes/No              |
|                               | (eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola]) |                     |
|                               | High intake of salami                                                 | Yes/No              |
|                               | (eats cured meats more than once a week [salami, mortadella, sausage, frankfurters . . . ]) |                     |
|                               | Poor vegetable intake                                                 | Yes/No              |
|                               | (less than 2 times per day)                                           |                     |
|                               | Poor fruit intake                                                     | Yes/No              |
|                               | (less than 3 whole fruits per day)                                    |                     |
| **Microsatellite instability** | Yes/No                                                                 |                     |
| **Notes**                     |                                                                        |                     |
### Allergies and Adverse Reactions

| FIELD                                | DETAIL                                           | NOTES/ALLOWED VALUES |
|--------------------------------------|--------------------------------------------------|-----------------------|
| **Allergies**                        | Yes/No                                           |                       |
| **Type**                             | • Drug                                           |                       |
|                                      | • MDC                                            |                       |
|                                      | • Not a Drug                                     |                       |
| **Active substance/molecule**        | [if drug or MDC allergy]                         |                       |
| **Commercial name**                  | [if drug or MDC allergy]                         |                       |
|                                     | Notes                                            |                       |
| **Previous adverse reactions**       | Yes/No                                           |                       |
| **Date**                             | Month/year [mm/yyyy]                             |                       |
| **Description**                      |                                                  |                       |
| **Grade**                            | • Mild                                           |                       |
|                                      | • Moderate                                       |                       |
|                                      | • Severe                                         |                       |
| **Timing**                           | • Early                                          |                       |
|                                      | • Late                                           |                       |
|                                     | Notes                                            |                       |

### Appendix C.2. Clinical Evaluation

| FIELD                                | DETAIL                                           | NOTES/ALLOWED VALUES |
|--------------------------------------|--------------------------------------------------|-----------------------|
| **Clinical Data**                    | Yes/No                                           |                       |
|                                      | • CT                                             |                       |
|                                      | • MRI                                            |                       |
|                                      | • US                                             |                       |
|                                      | • PET                                            |                       |
|                                      | • Others                                         |                       |
| **Previous examination**             | Yes/No                                           |                       |
| **Date**                             |                                                  |                       |
| **Notes**                            |                                                  |                       |
| **Rectal exploration performed**     | Yes/No                                           |                       |
| **Affected side**                    | • Front                                          |                       |
|                                      | • Right                                          |                       |
|                                      | • Left                                           |                       |
|                                      | • Rear                                           |                       |
| **Distance to anal verge**           | Numeric [cm]                                     |                       |
| **Distance to anorectal junction**   | Numeric [cm]                                     |                       |
| **Sphincter involvement**            | Yes/No                                           |                       |
| **Notes**                            |                                                  |                       |

### Trans-rectal ultrasound performed

| FIELD                                | DETAIL                                           | NOTES/ALLOWED VALUES |
|--------------------------------------|--------------------------------------------------|-----------------------|
| **Affected side**                    | • Front                                          |                       |
|                                      | • Right                                          |                       |
|                                      | • Left                                           |                       |
|                                      | • Rear                                           |                       |
| **Distance to anal verge**           | Numeric [cm]                                     |                       |
| **Distance to anorectal junction**   | Numeric [cm]                                     |                       |
| **Sphincter involvement**            | Yes/No                                           |                       |
| **Notes**                            |                                                  |                       |

### Histological examination of biopsy

| FIELD                                | DETAIL                                           | NOTES/ALLOWED VALUES |
|--------------------------------------|--------------------------------------------------|-----------------------|
| **Yes/No**                           | HistoType                                        |                       |
|                                      | (visible only if indicated Histologic examination of biopsy = yes) |                       |
| **Notes**                            |                                                  |                       |
### FIELD DETAIL NOTES/ALLOWED VALUES

| FIELD                  | DETAIL                  | NOTES/ALLOWED VALUES |
|------------------------|-------------------------|----------------------|
| CEA dosage             | Numeric                 |                      |
| Blood exam completed   | Numeric                 |                      |
| Creatinine             | Numeric                 |                      |
| Liver function         | • Normal                | • Compromised        |

#### Appendix C.3. Exam Technique

| FIELD                  | DETAIL                  | NOTES/ALLOWED VALUES |
|------------------------|-------------------------|----------------------|
| Examination Data       |                         |                      |
| Examination date       |                         |                      |
| Clinical indication    | Post neoadjuvant treatment |                      |
| Scanner field strength | 1.5T/3T                 |                      |
| Sequences              |                         |                      |
| (detail visible only if DWI is selected) | |                      |
|                        | • FSE T2 weighted in axial plane | |
|                        | • FSE T2 weighted in sagittal plane | |
|                        | • FSE T2 weighted in coronal plane | |
|                        | • FSE T1 weighted in axial plane | |
|                        | • DWI                    |                      |
|                        | • ADC                    |                      |
| b-value                | Numeric [s/mm²]          |                      |
| MDC                    |                         |                      |
| MDC (detail visible only if “Yes”) | |                      |
|                         | Yes/No                   |                      |
| Molecule               |                         |                      |
| Commercial name        |                         |                      |
| Volume                 | Numeric [mL]             |                      |
| Flow rate              | Numeric [mL/s]           |                      |
| Concentration          | Numeric [mg I/mL]        |                      |
| Notes                  |                         |                      |
| Premedication for allergy | Yes/No                 |                      |
|                         | Notes                    |                      |
| Creatinine             |                         |                      |
| GFR                    |                         |                      |
| (Glomerular Filtration Rate) | GFR = 141 \times min \left( \frac{\text{serum creatinine}}{\kappa}, 1 \right) \alpha \times \max \left( \frac{\text{serum creatinine}}{\kappa}, 1 \right) - 1.209 \times 0.993 \text{Age} \times \text{Gender} \times \text{Race} https://www.merckmanuals.com/medical-calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021 | |
| Preventive hydration   | Yes/No                   |                      |
|                         | Notes                    |                      |

#### ADVERSE EVENTS

| FIELD                  | DETAIL                  | NOTES/ALLOWED VALUES |
|------------------------|-------------------------|----------------------|
| Ongoing adverse events |                         |                      |
| (detail visible only if “Yes”) | |                      |
| Grade                  |                         |                      |
| Timing                 |                         |                      |
| Date and event time    |                         |                      |
| Master (Symptoms are generally self-limiting without evidence of progression and should be monitored) | |                      |
| Moderate (Symptoms are more pronounced and some can become severe if left untreated) | |                      |
| Severe (Symptoms are often life-threatening) | |                      |
| Early                  |                         |                      |
| Late                   |                         |                      |
| Numeric [min] (optional) |                         |                      |
| FIELD                          | DETAIL                                                                 | NOTES/ALLOWED VALUES |
|-------------------------------|------------------------------------------------------------------------|-----------------------|
| Ongoing adverse events       | **Type**                                                               | **ALLERGIC/ALLERGIC-LIKE** |
|                               | mild                                                                   | mild                  |
|                               | • Ponfi sparse/itchy                                                   |                      |
|                               | • Skin edema                                                          |                      |
|                               | • Mild itching/velvety in the throat                                   |                      |
|                               | • Nasal congestion                                                    |                      |
|                               | • Sneezing                                                            |                      |
|                               | • Conjunctivitis                                                      |                      |
|                               | • Runny nose                                                          |                      |
|                               | **Moderate**                                                          |                      |
|                               | • Widespread wheals/intense itching                                   |                      |
|                               | • Diffuse skin erythema                                               |                      |
|                               | • Facial edema without dyspnea                                         |                      |
|                               | • Feeling of suffocation or hoarseness                                 |                      |
|                               | • Shortness of breath/mild bronchospasm without hypoxia               |                      |
|                               | **Severe**                                                            |                      |
|                               | • Dyspnea                                                             |                      |
|                               | • Erythema—diffuse mucosal-cutaneous manifestations                   |                      |
|                               | • Laryngeal edema with stridor and/or hypoxia                         |                      |
|                               | • Shortness of breath/bronchospasm                                     |                      |
|                               | • Significant hypoxia                                                 |                      |
|                               | • Anaphylactic shock (severe hypotension and bradycardia-arrhythmia)  |                      |
|                               | **NOT ALLERGIC**                                                      |                      |
|                               | **Mild**                                                              |                      |
|                               | • Slight limited nausea/vomiting                                       |                      |
|                               | • Chills/heat/transient redness                                        |                      |
|                               | • Headache/dizziness/anxiety/impaired taste                           |                      |
|                               | • Mild increase in blood pressure                                      |                      |
|                               | • Self-resolving vaso-vagal reaction                                   |                      |
|                               | **Moderate**                                                          |                      |
|                               | • Prolonged nausea/vomiting                                           |                      |
|                               | • High blood pressure                                                 |                      |
|                               | • Isolated chest pain                                                 |                      |
|                               | • Vaso-vagal reaction                                                 |                      |
|                               | **Severe**                                                            |                      |
|                               | • Vaso-vagal reaction resistant to treatment                          |                      |
|                               | • Arrhythmia                                                          |                      |
|                               | • Seizures                                                            |                      |
|                               | • Marked arterial hypertension                                        |                      |
| Treatment Type                | • Observation                                                         |                      |
|                               | • Drug administration + field notes for detail                        |                      |
|                               | • Called resuscitator                                                 |                      |
| Event resolution              | • Spontaneously                                                       |                      |
|                               | • After therapy                                                       |                      |
|                               | • After hospitalization                                               |                      |
|                               | • Other                                                               |                      |
| Notes                         |                                                                        |                      |

**Appendix C.4. Report**

| FIELD                          | DETAIL                                                                 | NOTES/ALLOWED VALUES |
|-------------------------------|------------------------------------------------------------------------|-----------------------|
| Tumor Staging                 |                                                                        |                       |
| Primary tumor visible on imaging | Yes/No                                                                  |                       |
| Position                      | **Type**                                                               | **Low**               |
|                               | • Low                                                                  |                       |
|                               | • Medium                                                               |                       |
|                               | • High                                                                 |                       |
| Notes                         |                                                                        |                       |
| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|----------------------|
| Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm] |
| Craniocaudal tumor length | Numeric [cm] |
| Morphology Type | Solid—polypoid, Solid—(semi-)annular, Mucinous |
| Location From | Numeric [o’clock] |
| Location To | Numeric [o’clock] |
| Local invasion Type | T1–2, T3, T4, T3a or T3b ($\leq$ 5 mm extramural growth), T3c or T3d (>5 mm extramural growth), T4a: peritoneal involvement, T4b: infiltration of the adjacent organs |
| Notes | |
| Anal sphincter complex involvement (detail visible only if “Yes”) Internal sphincter, Intersphincteric plane, External sphincter, Height sphincter invasion High, Medium, Distal |
| CRM Involvement The shortest distance between the outermost part of the rectal tumor and the MRF Numeric [mm] Free if >2 mm, Threatened/involved if $\leq$ 2 mm |
| Margins Type (multiple choice) Involvement, Not Involvement |
| Minimum distance localization Type Front, Back, Lateral, Right, Left |
| Relationship with anterior peritoneal reflection Type Above, Below (reversal of the MCR) |
| LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESOCOT ADIPOSE TISSUE |
| Lymph node metastases Degree of suspicion short axis diameter $\geq$ 9 mm, nodes with short axis diameter 5–8 mm and at least 2 morphologic criteria, nodes with short axis diameter <5 mm and all 3 morphologic criteria |
| Lymph node metastases (detail visible only if number > 0) Location Mesorectal, Extramesorectal |
| Lymph node metastases (detail visible only if “short axis diameter < 9 mm”) Morphologic suspicious criteria Round shape, Irregular shape, Heterogeneous signal |
| Tumor deposits into mesorectal space (detail visible only if “Yes”) Notes Yes/No |
| Extramural vascular invasion Notes Yes/No |
| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Positive lymph nodes with extracapsular extension | Yes/No      |                      |
|                                            | Numeric     |                      |
|                                            | Notes       |                      |
|                                            | Notes       |                      |

**Conclusion**

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Diagnosis                                 | cT, N, M, Stage (TNM classification, 8th Edition, AJCC-UICC 2017) |                      |
|                                            | T0          |                      |
|                                            | Tis         |                      |
|                                            | T1          | Diagnosis            |
|                                            | T2          |                      |
|                                            | T3          |                      |
|                                            | T4          |                      |

**Annotations and comments**

**Appendix C.5. Images**

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Significant key images                    | Images      |                      |

**Appendix D**

**Appendix D.1. Patient Clinical Data**

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| **Anthropometric Data**                   |             |                      |
| Weight                                    | Numeric [Kg]|                      |
| Height                                    | Numeric [cm]|                      |
| **BMI**                                   | Numeric     | [calculated automatically] |
| **BSA**                                   | Numeric     | [calculated automatically] |
| Age                                       | Numeric     |                      |
| age class                                 |             | <50                  |
|                                            |             | >50                  |

**Personal Ratings**

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Family History for colorectal cancer      |             |                      |
| (detail visible only if “Yes” and repeatable) | Yes/No      |                      |
| Kind of relationship                       |             | Mother               |
|                                            |             | Father               |
|                                            |             | Brothers Sisters     |
|                                            |             | Maternal grandparents|
|                                            |             | Paternal grandparents|
|                                            |             | Uncles/aunts         |
|                                            |             | Other                |
| Notes                                     |             |                      |

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Family History for cancer                 |             |                      |
| (detail visible only if “Yes” and repeatable) | Yes/No      |                      |
| Kind of relationship                       |             | Mother               |
|                                            |             | Father               |
|                                            |             | Brothers Sisters     |
|                                            |             | Maternal grandparents|
|                                            |             | Paternal grandparents|
|                                            |             | Uncles/aunts         |
|                                            |             | Other                |
| Notes                                     |             |                      |

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Personal background for other malignancies|             | Yes/No               |
| Notes                                    |             |                      |

| Field                                      | Detail      | Notes/Allowed Values |
|-------------------------------------------|-------------|----------------------|
| Hereditary genetic alterations            |             | Yes/No               |
| (detail visible only if “Yes” and repeatable) | Type        | Polyposis associated with MutYH or MAP mutation |
|                                            |             | Colon attenuated polyposis (AFAP)               |
|                                            |             | Classic colon polyposis (FAP)                   |
|                                            |             | Lynch syndrome                                     |
| Notes                                     |             |                      |
### Predisposing pathologies (detail visible only if “Yes” and repeatable)

**Type**
- Diabetes
- Hypercholesterolemia
- Hypertension
- Hypertriglyceridemia
- Crohn’s disease
- Rectal ulcerative colitis
- Metabolic syndrome

**Notes**

### Risk factors (detail visible only if “Yes” and repeatable)

**Smoker**

| Field                      | Detail                                                                 | Notes/Allowed Values |
|----------------------------|------------------------------------------------------------------------|----------------------|
| Current Smoker             | Yes/No                                                                 | Smoker Current       |
| Former Smoker              | Yes/No                                                                 | Smoker Former        |
| Number of cigarettes per day [if current smoker] | weak (<15)                                                                 | Yes/No |
|                           | strong (≥15)                                                            | Yes/No               |
| Years of smoking           | Numeric                                                               | Yes/No               |
| Number of years of cessation [if ex-smoker] | ≤15                                                                       | Yes/No               |
|                           | >15                                                                   | Yes/No               |
| pack-year [if ex-smoker or current smoker] | [calculated automatically] (No. of cigarettes per day × smoke years/20) | Yes/No               |
| Electronic cigarette      | Yes/No                                                                 | Yes/No               |
| Number of refills per day  | Numeric                                                               | Yes/No               |
|                           | [if electronic cigarette = yes]                                       | Yes/No               |
| Number of years            | Numeric                                                               | Yes/No               |
|                           | [if electronic cigarette = yes]                                       | Yes/No               |

**Notes**

### ALLERGIES AND ADVERSE REACTIONS

**Microsatellite instability**

| Field               | Detail | Notes |
|---------------------|--------|-------|
| Microsatellite instability | Yes/No | Notes |
| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|-----------------------|
| **Allergies** (detail visible only if “Yes” and repeatable) | Yes/No | |
| Type | • Drug | |
|       | • MDC | |
|       | • Not a Drug | |
| Active substance/molecule | [if drug or MDC allergy] | |
| Commercial name | [if drug or MDC allergy] | |
| Notes | | |
| **PREVIOUS adverse reactions** (detail visible only if “Yes” and repeatable) | Yes/No | |
| Date | Month/year [mm/yyyy] | |
| Description | | |
| Grade | • Mild | |
|       | • Moderate | |
|       | • Severe | |
| Timing | • Early | |
|       | • Late | |
| Notes | | |

Appendix D.2. Clinical Evaluation

| FIELD | DETAIL | NOTES/ALLOWED VALUES |
|-------|--------|-----------------------|
| **Clinical Data** | | |
| Previous examination (detail visible only if “Yes” and repeatable) | Yes/No | |
| Type | • CT | |
|       | • MRI | |
|       | • US | |
|       | • PET | |
|       | • Others | |
| Date | | |
| Notes | | |
| Rectal exploration performed (detail visible only if “Yes”) | Yes/No | |
| Affected side | • Front | |
|       | • Right | |
|       | • Left | |
|       | • Rear | |
| Distance to anal verge | Numeric [cm] | |
| Distance to anorectal junction | Numeric [cm] | |
| Sphincter involvement | Yes/No | |
| Notes | | |
| Trans-rectal ultrasound performed (detail visible only if “Yes”) | Yes/No | |
| Affected side | • Front | |
|       | • Right | |
|       | • Left | |
|       | • Rear | |
| Distance to anal verge | Numeric [cm] | |
| Distance to anorectal junction | Numeric [cm] | |
| Sphincter involvement | Yes/No | |
| Notes | | |
| Histological examination of biopsy | Yes/No | |
| Notes | | |
| CEA dosage | Numeric | |
| Blood exam completed | Numeric | |
| Creatinine | Numeric | |
| Liver function | • Normal | |
|       | • Compromised | |
## Appendix D.3. Exam Technique

| FIELD                      | DETAIL                                      | NOTES/ALLOWED VALUES |
|----------------------------|---------------------------------------------|----------------------|
| Examination Data           |                                             |                      |
| Examination date           |                                             |                      |
| Clinical indication        | Post neoadjuvant treatment                  |                      |
| Timing of Re-assessment    | weeks                                       |                      |
| Sequences                  | FSE T2 weighted in axial plane              |                      |
|                            | FSE T2 weighted in sagittal plane           |                      |
|                            | FSE T2 weighted in coronal plane            |                      |
|                            | FSE T1 weighted in axial plane              |                      |
|                            | DWI                                         |                      |
|                            | ADC                                         |                      |
| MDC                        | Yes/No                                      |                      |
| Active principle           |                                             |                      |
| Commercial name            |                                             |                      |
| Dosage                     | Numeric [mL]                                |                      |
| Flow rate                  | Numeric [mL/s]                              |                      |
| Concentration              | Numeric [mg I/mL]                           |                      |
| Notes                      |                                             |                      |
| Premedication for allergy  | Yes/No                                      |                      |
| Notes                      |                                             |                      |
| Preventive hydration for kidney failure | Yes/No |                      |
| Notes                      |                                             |                      |
| GFR                        | Numeric [mL/min]                             |                      |
| (Glomerular Filtration Rate) | GFR = 141 × min (serum creatinine/kappa, 1) alpha |                      |
|                            | × max (serum creatinine/kappa, 1) − 1.209 × 0.993Age |                      |
|                            | × Gender × Race                             |                      |
|                            | [https://www.merckmanuals.com/medical-     |                      |
|                            | calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021] |                      |
| ADVERSE EVENTS             | Yes/No                                      |                      |
| Date and event time        |                                             |                      |
| Ongoing adverse events     | Mild (Symptoms are generally self-limiting without evidence of progression and should be monitored) |                      |
| (detail visible only if “Yes”) | Moderate (Symptoms are more pronounced and some can become severe if left untreated) |                      |
|                            | Severe (Symptoms are often life-threatening) |                      |
| Grade                      | Early                                       |                      |
| Timing                     | Late                                        |                      |
|                            | Numeric [min] (optional)                    |                      |
### Ongoing adverse events (detail visible only if “Yes”)

| Field                          | Detail                     | Notes/Allowed Values |
|-------------------------------|----------------------------|----------------------|
| **Type**                      |                            |                      |
| Allergic/allergic-like        | mild                       |                      |
| • Ponfi sparse/itchy         |                            |                      |
| • Skin edema                 |                            |                      |
| • Mild itching/velvety in the throat |              |                      |
| • Nasal congestion           |                            |                      |
| • Sneezing                   |                            |                      |
| • Conjunctivitis             |                            |                      |
| • Runny nose                 |                            |                      |
| Moderate                     | Widespread wheals/intense itching |                      |
| • Diffuse skin erythema      |                            |                      |
| • Facial edema without dyspnea |                       |                      |
| • Feeling of suffocation or hoarseness |          |                      |
| • Shortness of breath/mild bronchospasm without hypoxia | |                      |
| Severe                       | Dyspnea                    |                      |
| • Erythema—diffuse mucosal-cutaneous manifestations | |                      |
| • Laryngeal edema with stridor and/or hypoxia | |                      |
| • Shortness of breath/bronchospasm |                    |                      |
| • Significant hypoxia        |                            |                      |
| • Anaphylactic shock (severe hypotension and bradycardia-arrhythmia) | |                      |
| Not allergic                 | Slight limited nausea/vomiting |                      |
| • Chills/heat/transient redness |                        |                      |
| • Headache/dizziness/anxiety/impaired taste | |                      |
| • Mild increase in blood pressure |                       |                      |
| • Self-resolving vaso-vagal reaction |                    |                      |
| Moderate                     | Prolonged nausea/vomiting  |                      |
| • High blood pressure        |                            |                      |
| • Isolated chest pain        |                            |                      |
| • Vaso-vagal reaction        |                            |                      |
| Severe                       | Vaso-vagal reaction resistant to treatment |                      |
| • Arrhythmia                 |                            |                      |
| • Seizures                   |                            |                      |
| • Marked arterial hypertension|                            |                      |
| Treatment Type               | Observation                |                      |
| • Drug administration + field notes for detail |   |                      |
| • Called resuscitator        |                            |                      |
| Event resolution             | Spontaneously              |                      |
| • After therapy              |                            |                      |
| • After hospitalization      |                            |                      |
| • Other                      |                            |                      |
| Notes                        |                            |                      |

### Appendix D.4. Report

| Field                          | Detail                     | Notes/Allowed Values |
|-------------------------------|----------------------------|----------------------|
| **Tumor Staging**             |                            |                      |
| Remaining tumor               | No, fully normalized rectal wall (complete response) |                      |
|                               | No, fibrotic thickening of the wall without a residual mass (complete or near full response) |                      |
|                               | Yes, residual mass (and/or high signal on DWI) |                      |
| Notes                         |                            |                      |
| **MRI Tumor Regression Grade (TRG) Dworak** | |                      |
|                               | TRG 1 (Complete radiologic response): no evidence of tumor |                      |
|                               | TRG 2 (Good response): dense fibrosis (>75%); no obvious residual tumor |                      |
|                               | TRG 3 (Moderate response): >50% fibrosis or mucin with a minority of visible tumor |                      |
|                               | TRG 4 (Slight response): <50% fibrosis or mucin with a majority of visible tumor |                      |
|                               | TRG 5 (No response): No post-treatment changes (same as before treatment) |                      |
### Field Details

**Restricted Diffusion appearance**
- Yes
- No

**Mucin Response**
- Mucin (or colloid degeneration) response in non-mucinous tumor after chemoradiotherapy
- Mucinous tumor without response

**Healthy rectal wall appearance**
- Layered appearance due to edema
- No difference from pretreatment

**ycT-stage**
- ycT1–2
- ycT3—ycT3a or ycT3b (extramural extension ≤ 5 mm)
- ycT3—ycT3c or ycT3d (extramural extension > 5 mm)
- ycT4, extension to adjacent organs

### Notes

**Distance from the inferior border of the tumor to the anal verge**
Numeric [cm]

**Distance from the inferior border of the tumor to the anorectal junction**
Numeric [cm]

**Cranio-caudal tumor length**
Numeric [cm]

**Anal sphincter complex involvement (detail visible only if “Yes”)**

| Type (multiple choice) | Localisation |
|------------------------|--------------|
| Internal sphincter     | High         |
| Intersphincteric plane | Medium       |
| External sphincter     | 1/3 away from the channel |

**CRM Involvement**
The shortest distance between the outermost part of the rectal tumor and the MRF
Numeric [mm]

**Margins**
- Involvement
- Not Involvement

**Localisation**
- Front
- Back
- Lateral
- Right
- Left

**O-clock position**
- Above
- Below (reversal of the MCR)

### Lymph Nodes and Tumor Deposits: Local Metastatic Diffusion Within MesoCaT Adipose Tissue

**Lymph node metastases (detail visible only if “Yes”)**

| Type | Number of suspected residual mesorectal lymph nodes (≥5 mm) | Number of suspected extra mesorectal lymph nodes (≥5 mm) |
|------|------------------------------------------------------------|----------------------------------------------------------|
| ycN0 | (no node remaining or only nodes ≤ 5 mm)                  |                                                           |
| ycN+ | (presence of nodes with short axis diameter ≥ 5 mm)       |                                                           |

**Tumor deposits into mesorectal space (detail visible only if “Yes”)**
Notes

**Extramural vascular invasion**
Notes

**Yes/No**
Cancers 2021, 13, 2135

Appendix D.5. Images

References

1. Gunderman, R.B.; McNeive, L.R. Is structured reporting the answer? *Radiology* 2014, 273, 7–9. [CrossRef] [PubMed]

2. (ESR) ESoR. Good practice for radiological reporting. Guidelines from the European Society of Radiology (ESR). *Insights Imaging* 2011, 2, 93–96. [CrossRef] [PubMed]

3. Morgan, T.A.; Helibrun, M.E.; Kahn, C.E. Reporting initiative of the Radiological Society of North America: Progress and new directions. *Radiology* 2014, 273, 642–645. [CrossRef]

4. Dunnick, N.R.; Langlotz, C.P. The radiology report of the future: A summary of the 2007 Intersociety Conference. *J. Am. Coll. Radiol.* 2008, 5, 626–629. [CrossRef]

5. Ernst, B.P.; Hodeib, M.; Strieth, S.; Künzel, J.; Bischof, F.; Hackenberg, B.; Huppertz, T.; Weber, V.; Bahr, K.; Eckrich, J.; et al. Structured reporting of head and neck ultrasound examinations. *BMC Med. Imaging* 2019, 19, 25. [CrossRef] [PubMed]

6. Brown, P.J.; on behalf of the YCR BCIP Study Group; Rossington, H.; Taylor, J.; Lambregts, D.M.J.; Morris, E.; West, N.P.; Quirke, P.; et al. The Updated Version of the AIOM Guidelines. Available online: https://www.aiom.it/linee-guida-aiom/ (accessed on 21 January 2021).

7. Pinto Dos Santos, D.; Baeßler, B. Big data, artificial intelligence, and structured reporting. *Ann. Surg.* 2018, 259, 188–193. [CrossRef] [PubMed]

8. Beets-Tan, R.G.H.; Lambregts, D.M.J.; Maas, M.; Bipat, S.; Barbaro, B.; Curvo-Semedo, L.; Fenlon, H.M.; Gollub, M.J.; Gourtsoyianni, S.; Halligan, S.; et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur. Radiol.* 2018, 28, 1465–1475. [CrossRef]

9. Gollub, M.J.; Arya, S.; Beets-Tan, R.G.; DePrisco, G.; Gonen, M.; Jhaveri, K.; Kassam, Z.; Kaur, H.; Kim, D.; Knezevic, A.; et al. Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. *Abdom. Radiol.* 2018, 43, 2893–2902. [CrossRef]

10. Horvat, N.; Carlos Tavares Rocha, C.; Clemente Oliveira, B.; Petkovska, I.; Gollub, M.J. MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management. *Radiographics* 2019, 39, 367–387. [CrossRef]

11. Jia, X.X.; Wang, Y.; Cheng, J.; Yao, X.; Yin, M.-J.; Zhou, J.; Ye, Y.-J. Low-Versus High-Risk Rectal cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy. *AJR Am. J. Roentgenol.* 2018, 211, 327–334. [CrossRef] [PubMed]

12. Taylor, F.G.; Quirke, P.; Heald, R.J.; Moran, B.; Blomqvist, L.; Swift, I.; Sebag-Montefiore, D.J.; Tekkis, P.; Brown, G. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: A prospective, multicenter, European study. *Ann. Surg.* 2011, 253, 711–719. [CrossRef]

13. Giannini, V.; Mazzetti, S.; Bertotto, I.; Chiarenza, C.; Cauda, S.; Delmastro, E.; Bracco, C.; Di Dia, A.; Leone, F.; Medico, E.; et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 876–888. [CrossRef] [PubMed]

14. Ciolina, M.; Caruso, D.; De Santis, D.; Zerunian, M.; Rengo, M.; Alfieri, N.; Musio, D.; De Felice, F.; Ciardi, A.; Tombolini, V.; et al. Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer: Role of perfusion parameters in the assessment of response to treatment. *Radiol. Med.* 2019, 124, 331–338. [CrossRef] [PubMed]

15. The Updated Version of the AIOM Guidelines. Available online: https://www.aiom.it/linee-guida-aiom/ (accessed on 21 January 2021).

16. Weiser, M.R. AJCC 8th Edition: Colorectal Cancer. *Ann. Surg. Oncol.* 2018, 25, 1454–1455. [CrossRef]

17. Dalkey, N.; Helmer, O. An Experimental Application of the DELPHI Method to the Use of Experts. 1963. Available online: https://www.rand.org/content/dam/rand/pubs/research_memoranda/2009/RM727.1.pdf (accessed on 21 January 2021).
18. Kahn, C.E.; Genereaux, B.; Langlotz, C.P. Conversion of Radiology Reporting Templates to the MRRT Standard. J. Digit. Imaging 2015, 28, 528–536. [CrossRef]

19. Becker, G. Creating comparability among reliability coefficients: The case of Cronbach alpha and Cohen kappa. Psychol. Rep. 2000, 87, 1171–1182. [CrossRef]

20. Cronbach, L.J. Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16, 297–334. [CrossRef]

21. (ESR) ESoR. ESR paper on structured reporting in radiology. Insights Imaging 2018, 9, 1–7. [CrossRef]

22. Chen, J.Y.; Sippel Schmidt, T.M.; Carr, C.D.; Kahn, C.E. Enabling the Next-Generation Radiology Report: Description of Two New System Standards. Radiographics 2017, 37, 2106–2112. [CrossRef]

23. Cusumano, D.; Meijer, G.; Lenkowicz, J.; Chiloiro, G.; Boldrini, L.; Masciocchi, C.; Dinapoli, N.; Gatta, R.; Casà, C.; Damiani, A.; et al. A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer. Radiol. Med. 2021, 126, 421–429. [CrossRef]

24. Crimi, F.; Capelli, G.; Spolverato, G.; Bao, Q.R.; Fiorio, A.; Rossi, S.M.; Cecchin, D.; Albertoni, L.; Campi, C.; Pucciarelli, S.; et al. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC). Radiol. Med. 2020, 125, 1216–1224. [CrossRef] [PubMed]

25. Cusumano, D.; Dinapoli, N.; Boldrini, L.; Chiloiro, G.; Gatta, R.; Masciocchi, C.; Lenkowicz, J.; Casà, C.; Damiani, A.; Azario, L.; et al. Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer. Radiol. Med. 2018, 123, 286–295. [CrossRef]

26. Horvat, N.; Veeraraghavan, H.; Pelossof, R.A.; Fernandes, M.C.; Arora, A.; Khan, M.; Marco, M.; Cheng, C.-T.; Gonen, M.; Pernicka, J.S.G.; et al. Radiogenomics of rectal adenocarcinoma in the era of precision medicine: A pilot study of associations between qualitative and quantitative MRI imaging features and genetic mutations. Eur. J. Radiol. 2019, 113, 174–181. [CrossRef] [PubMed]

27. Caruso, D.; Zerunian, M.; Ciolina, M.; de Santis, D.; Rengo, M.; Soomro, M.H.; Giunta, G.; Conforto, S.; Schmid, M.; Neri, E.; et al. Haralick’s texture features for the prediction of response to therapy in colorectal cancer: A preliminary study. Radiol. Med. 2018, 123, 161–167. [CrossRef]

28. Fornell-Perez, R.; Vivas-Escalona, V.; Aranda-Sanchez, J.; Gonzalez-Dominguez, M.C.; Rubio-Garcia, J.; Aleman-Flores, P.; Lozano-Rodriguez, A.; Porcel-de-Peralta, G.; Loro-Ferrer, J.F. Primary and post-chemoradiotherapy MRI detection of extramural venous invasion in rectal cancer: The role of diffusion-weighted imaging. Radiol. Med. 2020, 125, 522–530. [CrossRef] [PubMed]

29. De Cecco, C.N.; Ciolina, M.; Caruso, D.; Rengo, M.; Ganeshan, B.; Meinel, F.G.; Musio, D.; De Felice, F.; Tombolini, V.; Laghi, A. Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumor response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: Initial experience. Abdom. Radiol. 2016, 41, 1728–1735. [CrossRef] [PubMed]

30. Caruso, D.; Zerunian, M.; De Santis, D.; Biondi, T.; Paolantonio, P.; Rengo, M.; Bellini, D.; Ferrari, R.; Ciolina, M.; Lucertini, E.; et al. Magnetic Resonance of Rectal cancer Response to Therapy: An Image Quality Comparison between 3.0 and 1.5 Tesla. Biomed Res. Int. 2020, 2020, 9842732. [CrossRef]

31. Schwartz, L.H.; Panicek, D.M.; Berk, A.R.; Li, Y.; Hricak, H. Improving communication of diagnostic radiology findings through structured reporting. Radiology 2011, 260, 174–181. [CrossRef]

32. Marcovic, P.A.; Taylor, G.A. Journal Club: Structured radiology reports are more complete and more effective than unstructured reports. AJR Am. J. Roentgenol. 2014, 203, 1265–1271. [CrossRef]

33. Ernst, B.P.; Strieth, S.; Katzer, F.; Hodeib, M.; Eckrich, J.; Bahr, K.; Rader, T; Künzel, J.; Froelich, M.F.; Matthias, C.; et al. The use of structured reporting of head and neck ultrasound ensures time-efficiency and report quality during residency. Eur. Arch. Otorhinolaryngol. 2020, 277, 269–276. [CrossRef] [PubMed]

34. Goldberg-Stein, S.; Chernyak, V. Adding Value in Radiology Reporting. J. Am. Coll. Radiol. 2019, 16, 1292–1298. [CrossRef] [PubMed]

35. Brady, A.P. Radiology reporting-from Hemingway to HAL? Insights Imaging 2018, 9, 237–246. [CrossRef]

36. Weiss, D.L.; Langlotz, C.P. Structured reporting: Patient care enhancement or productivity nightmare? Radiology 2008, 249, 739–747. [CrossRef] [PubMed]

37. Faggioni, L.; Coppola, F.; Ferrari, R.; Neri, E.; Regge, D. Usage of structured reporting in radiological practice: Results from an Italian online survey. Eur. Radiol. 2017, 27, 1934–1943. [CrossRef] [PubMed]